1 June 2021
Cancer is a systemic disease. This means it is important to treat not just the obvious tumor
mass but also the systemic cellular networks that nurture the tumor. Surprisingly, most
cancer treatment plans ignore the systemic networks.
Targeting systemic tumor networks will be difficult, requiring combinations of combinations of
therapy. We will need different therapeutic strategies for the primary tumor and many of the
systemic networks. Each type of therapy may need to consist of combinations of treatments
to block a sufficient number of steps in the web-like pathways that exist for each cellular
function.
This subject was discussed in the abstract below, which was not accepted at a recent
conference. Although disappointing, the advantage of this rejection is that I can publish it
now without any copyright restrictions. The full paper is at
http://www.natpernick.com/PancreaticcancerFeb2021.html. Please send your comments
to Nat@PathologyOutlines.com.
Monitoring Dysfunctional Networks To Support Curative Treatment of Pancreatic
Cancer
March 2021
Nat Pernick, M.D., Nat@PathologyOutlines.com
Context: Pancreatic cancer is a systemic disease with dysfunctional networks that must be
treated and monitored, in addition to the primary tumor.
Design: We calculated the population attribution fraction of pancreatic cancer risk factors
and reviewed their mechanisms of action within the context of complexity theory to determine
common features, principles of curative therapy and key network issues.
Results: Random chronic stress causes 25-35% of cases, non O blood group 17%, excess
weight 15%, cigarette smoking 15%, type 2 diabetes 9%, alcohol 5%, diet 5%, family history
/ germline 2% and chronic pancreatitis 1% (Table 1). Risk factors can be categorized into 5
“super promoters”: chronic inflammation, DNA alterations, random chronic stress / bad luck,
immune system dysfunction (individual or “societal”) and hormones. We identified key
systemic network issues that curative therapy must address and propose monitoring their
response to treatment: overall inflammatory process, immune system’s antitumor
capabilities, microenvironment (vasculature, inflammation, fibroblasts, extracellular matrix) of